Compare ASST & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | CAPR |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2022 | 2011 |
| Metric | ASST | CAPR |
|---|---|---|
| Price | $16.69 | $26.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $23.50 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 4.9M | 778.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $633,489.00 | N/A |
| Revenue This Year | $294.91 | N/A |
| Revenue Next Year | $12.16 | $3.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 128.67 | N/A |
| 52 Week Low | $0.49 | $4.30 |
| 52 Week High | $19.75 | $40.37 |
| Indicator | ASST | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 42.27 |
| Support Level | $14.32 | $25.33 |
| Resistance Level | $17.89 | $30.21 |
| Average True Range (ATR) | 1.21 | 1.17 |
| MACD | -0.18 | -0.09 |
| Stochastic Oscillator | 67.74 | 34.75 |
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.